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Introduction
Lupus nephritis (LN) is a major cause of morbidity and 
mortality in patients with systemic lupus erythematosus 
(SLE). Th   e general consensus is that 60% of lupus patients 
will develop clinically relevant nephritis at some time in 
the course of their illness [1]. Prompt recognition and 
treatment of renal disease is important, as early response 
to therapy is correlated with better outcome [2]. Th  e 
present review summarizes our current understanding of 
SLE pathogenesis, summarizes how the disease is 
diagnosed and treated, and expands on new emerging 
therapies.
Epidemiology of lupus nephritis
Most SLE patients develop nephritis early in the course 
of their disease. Th   e vast majority of patients who develop 
nephritis are younger than 55 years, and children are 
more likely to develop severe nephritis than are elderly 
patients [3]. In a recent retrospective study, male sex, 
young age (<33 years), and non-European ancestry were 
found to be determinants of earlier renal disease in 
patients with SLE. Asian, African Caribbean, and African 
American ethnicities may present with more severe 
nephritis than other ethnic groups [4].
Diagnosis of lupus nephritis
Clinical features of lupus nephritis
Proteinuria is the characteristic feature of renal disease in 
lupus. In a comprehensive review of LN, proteinuria was 
reported in 100% of patients, with nephrotic syndrome 
being reported in 45 to 65% [5]. Microscopic hematuria 
was found to occur in about 80% of patients during the 
disease course, invariably associated with proteinuria. 
Macroscopic hematuria is rare in LN. Hypertension is 
not common but is present more frequently in patients 
with severe nephritis. About one-half of all patients with 
LN will have a reduced glomerular ﬁ  ltration rate, and 
occasionally patients present with acute kidney injury. 
Renal tubular function is often disturbed, resulting in 
urinary excretion of Tamm-Horsefall proteins, light 
chains and β2-microglobulin [5].
Clinical diagnosis of lupus nephritis
Ideally, urinary protein excretion is gauged using a 
24-hour urine collection. Although universally practiced, 
variable results may occur over a short period of time, 
probably due to changes in physical activity or collection 
errors. Th  e latter problem can be remedied by quanti-
fying total creatinine in the same 24-hour urine collec-
tion. Th  e total creatinine measurement should approxi-
mate values obtained in 24-hour urine collections from 
the same patient and should be comparable with average 
values obtained in population studies of men (20 mg/kg/
day) and women (15 mg/kg/day). Alternatively, the urinary 
protein excretion rate can be estimated by assaying the 
protein/creatinine ratio in a random daytime urinary 
sample. Th  is ratio approximates the total number of 
grams per day of proteinuria, but it would be optimal to 
conﬁ  rm the validity of this method in individual patients, 
as described [5].
Th  e urinary sediment is also useful for characterizing 
renal disease activity, since the presence of hematuria, 
leukocyturia or casts are typical only during periods of 
disease activity. Interestingly, in one large series of 520 
cases of SLE, red cell casts were only present in 39 cases 
(7.5% of patients). In descending order, the most common 
abnormal urinary sediment ﬁ   ndings in LN are leuko-
cyturia, hematuria, granular casts and hyaline casts [6].
A rising anti-DNA antibody titer and hypo-comple-
ment  emia, especially with low complement C3, are 
Abstract
Lupus nephritis is a major cause of morbidity 
and mortality in patients with systemic lupus 
erythematosus. The general consensus is that 60% 
of lupus patients will develop clinically relevant 
nephritis at some time in the course of their illness. 
Prompt recognition and treatment of renal disease is 
important, as early response to therapy is correlated 
with better outcome. The present review summarizes 
our current understanding of the pathogenic 
mechanisms underlying lupus nephritis and how the 
disease is currently diagnosed and treated.
© 2010 BioMed Central Ltd
Lupus nephritis: current update
Ramesh Saxena*, Tina Mahajan and Chandra Mohan*
REVIEW
*Correspondence: Ramesh.saxena@utsouthwestern.edu; 
Chandra.mohan@utsouthwestern.edu
Department of Internal Medicine, UT Southwestern Medical Center, 
5323 Harry Hines Boulevard, Dallas, TX 75390, USA
Saxena et al. Arthritis Research & Therapy 2011, 13:240 
http://arthritis-research.com/content/13/5/240
© 2011 BioMed Central Ltdstrong indicators of active lupus renal disease, although 
serology cannot be used in isolation to diagnose or 
monitor renal disease. Hypo-albuminemia accompanied 
by signiﬁ  cant proteinuria is a component of the nephrotic 
syndrome that may accompany active lupus renal disease. 
Hypercholesterolemia is another marker and also a 
clinical complication of the nephrotic syndrome that can 
accompany active LN [5].
Th  ere is increasing recognition of the importance of 
tubulo  interstitial injury in LN. In the majority of patients, 
the severity of interstitial inﬂ   ammation parallels the 
degree of involvement of the glomerulus. Tubular damage, 
ﬁ   brosis and atrophy can be associated with hyper-
uricemia and renal tubular acidosis [5].
Histologic diagnosis of lupus nephritis
Kidney biopsy is the mainstay for the diagnosis of LN. 
Material obtained by renal biopsy is evaluated by light 
microscopy, immunoﬂ  uorescence and electron micro  s-
copy. In many cases, renal biopsy is instrumental in 
establishing the diagnosis of SLE because nephritis can 
be the ﬁ  rst clinical manifestation of SLE in up to 15 to 
20% of patients [5]. In the majority of cases, however, the 
diagnosis of SLE is already established. In such situations, 
renal biopsy helps to establish a precise diagnosis of LN, 
the extent of histopathological chronicity and activity, 
disease prog  nosis, and also serves as a guide for therapy. 
Th  e appearance of any new markers of kidney disease 
such as proteinuria, hematuria, active urinary sediment 
or rise in serum creatinine in a SLE patient should also 
prompt a renal biopsy. Moreover, one should consider a 
follow-up biopsy in a stable patient with established LN if 
the aforesaid markers reappear or worsen.
Histologic classifi  cation of lupus nephritis
Because of the extremely diverse histopathology of LN, 
several classiﬁ  cations have been proposed over the past 
four decades – the earliest schemes being proposed by 
the World Health Organization (WHO) in 1974, further 
reﬁ  ned by Austin and colleagues [7,8]. In order to further 
standardize deﬁ   nitions and to facilitate uniformity in 
reporting, as well as to eliminate ambiguities and incon-
sistencies in the WHO classiﬁ  cation, the International 
Society of Nephrology/Renal Pathology Society (ISN/
RPS) classiﬁ    cation was formulated in 2003, as detailed in 
Table 1 [9]. Th  is  classiﬁ  cation deﬁ  nes more precisely all 
glomerulo  nephritis (GN) classes and clearly delineates 
activity and chronicity.
Two recent studies demonstrate the superior repro-
duci  bility of the ISN/RPS classiﬁ  cation compared with 
the WHO classiﬁ  cation of LN [10,11]. In a large study 
involving 20 centers in the UK, renal pathologists classi-
ﬁ  ed cases of LN using the WHO system and then re-
classiﬁ   ed the same cases using the ISN/RPS 2003 
classi ﬁ  cation scheme one year later. A signiﬁ  cantly higher 
inter  observer reproducibility was observed using the 
ISN/RPS (2003) classiﬁ   cation than using the modiﬁ  ed 
WHO (1982) classiﬁ  cation [10].
Pathogenesis of lupus nephritis
Multiple mechanisms lead to LN, as reviewed elsewhere 
[12-14]. Th  e pathogenic events leading to LN can be 
parsed into two phases: systemic events in the immune 
system, and local events in the end organs (see Figure 1) . 
Th   e present review focuses on the cellular and molecular 
mechanisms that drive LN pathogenesis within the 
kidneys. Systemic events that orchestrate autoimmunity 
in SLE have been discussed in previous reviews [12-14], 
and will not be examined here.
Role of lymphocytes in lupus nephritis
T cells rank among the most conspicuous inﬂ  ammatory 
cells within the inﬂ  amed kidney in both SLE patients and 
mouse models of LN [15,16]. T cells cloned from the 
renal interstitium of MRL/lpr lupus mice have been 
shown to be autoreactive to renal antigens, to induce 
tubular epithelial and mesangial cell proliferation, and to 
produce cytokines such as IFNγ. Th   e pathogenic role of T 
cells within the kidneys has been demonstrated through 
the use of renal transplantation in MHC II-deﬁ  cient or 
CD4–/– lupus-prone mice and treatment with anti-CD4 
antibody [17-20]. Radeke and colleagues have demon-
strated that CD4+ T cells alone were suﬃ   cient as initiators 
and eﬀ  ectors in nephritis, by recognizing speciﬁ  c anti-
gens expressed within the glomeruli in an experimental 
mouse model of GN [21]. Although the antigen speciﬁ  city 
of intrarenal T cells in LN remains elusive, their eﬀ  ector 
Table 1. International Society of Nephrology/Renal 
Pathology Society classifi  cation of lupus nephritis
Class I  Minimal mesangial lupus nephritis
Class II  Mesangial proliferative lupus nephritis
Class III  Focal lupus nephritis (<50% glomeruli)
 III(A)  Active  lesions
  III(A/C)  Active and chronic lesions
 III(C)  Chronic  lesions
Class IV  Diff  use lupus nephritis (>50% glomeruli)
   Diff  use segmental (IV-S) or global (IV-G) 
 IV(A)  Active  lesions
  IV(A/C)  Active and chronic lesions
 IV(C)  Chronic  lesions
Class V  Membranous lupus nephritis
Class VI  Advanced sclerosing lupus nephritis 
    (≥90% globally sclerosed glomeruli without residual activity)
Adapted with premission from Weening et al. [9].
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of key cell-surface molecules and released cytokines.
Substantial evidence has been garnered for the patho-
genic role of CD40 ligand (CD40L), a member of the TNF 
family [21-26]. Th  e interaction of T-cell CD40L and 
CD40 ex  pressed on B cells plays a central role in humoral 
immune responses, having the capacity to induce clonal 
expan  sion, immunoglobulin class switch and diﬀ  eren-
tiation of B cells into plasma cells. In addition, CD40 is 
expressed on various eﬀ  ectors cells, such as macrophages, 
neutro  phils, dendritic cells (DCs), as well as resident 
renal cells, suggesting that CD40–CD40L interactions 
may be important in driving eﬀ  ector functions of other 
CD40-expressing cells within the kidneys [27-31]. CD40 
expression is markedly upregulated in proliferative lupus 
nephritis (PLN), in parallel with the increased presence 
of CD40L-bearing T cells in kidneys [29]. Activated 
T  cells co-cultured with renal tubular epithelial cell 
elaborate high levels of monocyte chemotactic protein-1, 
RANTES, IL-8 and interferon-inducible protein-10 from 
tubular epithelial cells, mediated in part through CD40–
CD40L interactions [30,31].
Among the cytokines released by T cells, a pre-
dominance of T-helper type 1 response has been docu-
mented by several studies in human LN [32-36], further 
supported by blocking (or gene ablation) studies in 
Figure 1. Molecular pathogenesis of lupus nephritis and potential therapeutic targets. Multiple steps lead to the pathogenesis of systemic 
lupus erythematosus (SLE). Captioned are two key sets of events underlying lupus nephritis (LN): one that engenders systemic autoimmunity, and 
another that drives end-organ infl  ammation and damage, as discussed in the text. Many of the cells and molecules in these pathogenic cascades 
also serve as attractive therapeutic targets, as detailed below. (1), (2) Dendritic cell (DC):T-cell and T-cell:B-cell interactions involve multiple co-
stimulatory molecules, including CD28/B7, ICOS/ICOSL, and CD40/CD40L; blockade of these co-stimulatory pathways is being tested as potential 
therapeutic strategies in lupus. (3) Blys/BAFF elaborated by myeloid cells binds to receptors on B cells, and drives autoantibody production in SLE. 
Blocking this axis is emerging as a promising therapeutic avenue, based on recent clinical trials. (4) CD20, CD22, and CD19 are receptors on B cells. 
Several trials are aimed at depleting B cells in SLE, using antibodies to these B-cell molecules. (5) The activation of autoreactive B cells (and other 
leukocytes) in SLE is mediated by several signaling axes; some of these have been therapeutically targeted with success in preclinical models of 
the disease, and in limited clinical trials. (6) Type 1 interferon-elicited gene signatures have emerged as a distinctive feature of SLE. Based on these 
exciting leads, therapeutics targeting this axis are currently in active trials. (7) Activated lymphocytes and myeloid cells utilize a variety of cell 
adhesion molecules in order to gain access to the target organs. Therapeutics targeting these adhesion molecules and/or vascular addressins have 
shown promise in preclinical models of lupus. (8) Clearance of immune complexes is mediated by complement (receptor) and Fc/FcR-mediated 
mechanisms; targeting these nodes has also shown promise in murine lupus. (9) Activated leukocytes (as well as resident renal cells) elaborate a 
large spectrum of disease mediators, including various cytokines and chemokines. Blockade of these mediators also hold promise in ameliorating 
LN, although we are in the infancy of these studies. CD40L, CD40 ligand; ICOS, inducible T-cell costimulator; ICOSL, inducible T-cell costimulator 
ligand; TCR, T-cell receptor.
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Page 3 of 12murine LN [37-40]. However, there is also some evidence 
that T-helper type 2 cytokines can also have a potential 
impact on LN. In several lupus-prone mouse models, 
engineering the upregulation of IL-4 worsens LN, where-
as IL-4 blockade or gene ablation ameliorates disease [41-
44]. Given that IL-4 has also been implicated in ﬁ  broblast 
proliferation, collagen gene expression, collagen synthesis 
and transforming growth factor beta (TGFβ) production, 
IL-4 may directly act upon renal cells to perpetuate 
glomerulosclerosis and chronic renal ﬁ  brosis,  partly 
through its eﬀ  ect on extracellular matrix generation [44].
Role of myeloid cells in lupus nephritis
Besides lymphocytes, myeloid cells also play critical roles 
in LN. Within normal human kidneys, at least two 
myeloid DC subtypes characterized by BDCA-1+DC-
SIGN+ and BDCA-1+DC-SIGN– and one plasmacytoid 
DC subtype deﬁ   ned as BDCA-2+DC-SIGN– are abun-
dantly located in the tubulointerstitium, but are rarely 
observed within the glomeruli [45-47]. In LN patients, 
strong renal inﬁ  ltrates of BDCA1+, BDCA3+ and BDCA4+ 
DCs have been reported. Notably, DCs inﬁ  ltrated both 
the tubulointerstitium and the glomeruli, with the extent 
of inﬁ  ltration correlating well with the severity of renal 
damage, notably class III/IV LN [48,49]. As in normal 
kidneys, DC inﬁ  ltrates in diseased human kidneys were 
mostly immature, marked by the absence of DC-LAMP+ 
cells [45,48]. In contrast to the renal DCs, a signiﬁ  cant 
decrease of myeloid DCs and/or plasmacytoid DCs has 
been observed in the peripheral blood of lupus patients 
[48-51]. It has been suggested that the decreased number 
of DCs in peripheral blood may be a consequence of their 
enhanced migration into the end organs [49,52]. Studies 
in murine models have also reported increased inﬁ  l-
tration of DCs into the renal glomeruli and tubulo-
interstitium [53-56]. Relatively little is known about how 
renal inﬁ  ltrating DCs contribute to the pathogenesis of 
LN, although a couple of scenarios have been suggested. 
First, DCs may elaborate proinﬂ   ammatory and pro-
ﬁ  brotic factors, including TNFα, IL-6, IL-1, IL-18, IFNα 
and TGFβ [57]. Second, DCs can migrate to local lymph 
nodes and potentially present renal autoantigens to 
T  lymphocytes [58]. Th  ird, since renal DCs express 
various co-stimulatory molecules such as CD40L, MHC 
II and chemokine receptors such as CCR1 and CCR5, 
they could directly interact with and activate intrinsic 
renal cells and other inﬁ  ltrating  inﬂ  ammatory  cells, 
hence perpetuating disease [58-60].
Macrophages represent a second myeloid cell type that 
is recruited to the kidneys in LN [54,61-63]. Recruited 
macrophages are located in both the glomerular tuft and 
tubulointerstitium, and constitute the major cell type in 
glomerular crescents [61-64]. Renal inﬁ  ltrating macro-
phages exhibit elevated expression of CD11b, OX40L, 
CD80 and CD86, being markers of disease onset in LN. 
Once recruited, activated macrophages could play a wide 
variety of roles in meditating renal injury, largely by 
secreting various proinﬂ  ammatory mediators (including 
TNF and IL-1), reactive oxygen species and proteolytic 
enzymes. Although the obligatory role for macrophages 
has been demonstrated in experimental GN models 
[65-68], whether they are equally essential for LN 
remains unknown.
Role of resident renal cells in lupus nephritis
Th   e major resident cells in the kidney include mesangial 
cells, endothelial cells and epithelial cells. Th  ese  intrinsic 
renal cells represent both the cause and the victim of 
various insults leading to GN [69,70]. Perhaps the most 
compelling evidence that intrinsic renal cells play an 
important role in immune-meditated GN has come from 
bone-marrow transfer or kidney-transplant studies in 
mice subjected to anti-glomerular basement membrane 
nephritis. Studies of this nature have helped outline the 
disease role of MHC II, TNF and Fn14 on intrinsic renal 
cells [71-73].
Beside these isolated examples, we know very little 
about whether other molecules need to be intrinsically 
expressed within resident renal cells in order for 
immune-mediated GN to ensue. Some studies have 
suggested that resident renal cells from lupus-prone mice 
are intrinsically aberrant; for example, it has been 
reported that mesangial cells from lupus mice have a 
decreased threshold for the production of inﬂ  ammatory 
mediators, and do indeed elaborate more monocyte 
chemo tactic  protein-1  and osteopontin [74-76]. We 
currently have no insights into whether intrinsic renal 
cells may be fundamentally diﬀ   er  ent in human LN 
compared with what we know about the role of 
inﬁ  ltrating leukocytes in LN. Th   erefore, our understand-
ing of how intrinsic renal cells contribute to disease is 
rudimentary.
Role of cytokines and chemokines in lupus nephritis
As alluded to above, cytokines have emerged as impor-
tant players in the pathogenesis of LN. Whereas some 
cytokines that aggravate LN may act predominantly in a 
systemic fashion (for example, BAFF), other cytokines 
such as IL-17, IFNα and TGFβ have been shown to have a 
role in systemic autoimmunity as well as local renal 
disease. Increased IL-17-producing T cells have been 
documented within the kidneys in both SLE patients and 
SNF1 lupus-prone mice, with disease treatment being 
associated with reduced numbers of these cells [77,78]. 
Several independent experiments have found peripheral 
blood mononuclear cells from SLE patients to exhibit a 
prominent type I interferon-inducible gene expression 
proﬁ  le, referred to as the interferon signature, supporting 
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in lupus pathogenesis [79-81]. Although IFN-I is known 
to impact systemic immunity in a variety of ways, recent 
evidence indicates that IFN-I produced by resident renal 
cells may be also contribute to renal inﬂ  ammation [82].
TGFβ is a potent multifunctional cytokine that exerts an 
anti-inﬂ  ammatory and immunosuppressive role systemi-
cally, but a proﬁ  brotic role locally within diseased kidneys. 
Th  e action of persistent, dysregulated TGFβ production 
on the extracellular matrix drives progressive renal disease 
in LN [83]. Elevated TGFβ expression has been found in 
SLE renal tissue, correlating well with histological activity 
[84-86]. Also, disease remission in LN is related to 
decreased renal TGFβ expression [85]. Th   e collective data 
in the ﬁ  eld strongly indicate that reduced TGFβ in immune 
cells predisposes mice to immune dysregulation and auto-
antibody production, where  as enhanced TGFβ expression 
within the kidneys leads to dysregulated tissue repair, 
progressive ﬁ  bro  genesis and eventual end-organ damage 
[87]. Hence, TGFβ is a double-edged sword – subduing 
systemic immunity, but aggravating chronic nephritis.
As discussed above, macrophages play a central role in 
mediating LN. Hence, not surprisingly, colony-stimulat-
ing factor-1 (CSF-1, the principal macrophage growth 
factor) and macrophage migration inhibitory factor – key 
proinﬂ   ammatory cytokines regulating macrophage 
recruitment – have also been documented as central 
players in LN. Renal resident cells, most notably tubular 
epithelial cells, are the primary source of CSF-1 during 
renal disease [88,89]. Increased renal expression of CSF-1 
has been noted before overt renal pathology and becomes 
more abundant with advancing LN [90]. Mechanistic 
studies in murine models have garnered direct experi-
mental support for a pathogenic role of CSF-1 and migra-
tion inhibitory factor in LN [91-98]. Other cytokines that 
have been shown to be important for antibody-mediated 
renal disease and/or LN include IL-1, IL-6, IL-10 and 
TNFα, as reviewed elsewhere [99]. Besides cytokines, a 
pathogenic role has also been assigned to two chemo-
kines – monocyte chemotactic protein-1 and CXCL12. 
Both chemokines are elevated within diseased kidneys in 
mice and patients with LN, while mechanistic studies in 
mice support their role in disease pathogenesis [100-113].
Since most of the above cytokines and chemokines can 
be elaborated systemically as well as locally within the 
kidneys, it remains to be established whether renal 
expression of any of these molecules is necessary for LN. 
Th  e complex pathogenic cascades leading to SLE lend 
themselves to therapeutic intervention at multiple nodes, 
some systemic and some intrarenal, some of which are 
discussed in Figure 1. Several of the indicated therapeutic 
strategies have only been tried in preclinical models of 
LN, whereas others are currently in active clinical trials, 
as discussed below. As we gain better insights into these 
molecular cascades and their druggability, the goal is to 
eventually identify the optimal combinatorial regimes 
that could potentially silence all critical pathways leading 
to disease.
Treatment of lupus nephritis
Before the advent of immunosuppressive regimens, a 
2-year survival rate <10% was observed in patients with 
diﬀ  use PLN treated with low-dose steroids [114]. Since 
then, the survival of patients with PLN has improved 
considerably due to earlier recognition of renal disease, 
aggressive immunosuppression and improved supportive 
care [115]. Numerous prognostic factors have been identi-
ﬁ  ed in LN. Among others, nonwhite race (for exam  ple, 
black, Afro-Caribbean, Hispanic), poor socio  economic 
status, uncontrolled hypertension, a high activity and 
chronicity index on kidney biopsy, renal impairment at 
baseline, poor initial response to therapy and nephritic 
relapses have been associated with poor outcome. Lack 
of adherence to therapy is an underestimated cause of 
treatment failure [116,117]. Th  e therapeutic goals for a 
patient with newly diagnosed LN are to achieve prompt 
renal remission using induction therapy, to avoid renal 
ﬂ  ares and chronic renal impairment using maintenance 
therapy, and to minimize treatment-associated toxicity. 
Th   ese goals are discussed further below.
Induction therapy with intravenous cyclophosphamide
In 1986, Austin and colleagues from the National Insti-
tutes of Health (NIH) published the results of a large 
randomized trial demon  strating the role of intravenous 
(i.v.) cyclophosphamide (CYC) as an induction therapy, 
as listed in Table 2 [118]. In a later NIH trial, combination 
therapy of i.v. methyl  prednisolone and i.v. CYC was 
shown to achieve a higher rate of renal remission than i.v. 
methylprednisolone alone [119]. After a median follow-
up of 11 years, none of the 20 patients who received 
combination therapy experi  enced end-stage renal disease 
(ESRD). Despite excellent eﬃ   cacy, i.v. CYC treatment is 
associated with a high rate of premature ovarian failure 
(ranging from 38 to 52% of women at risk), increased risk 
of severe infections, a signiﬁ  cant percentage of treatment 
failures and a high rate of renal relapse [120].
In order to reduce total CYC exposure and toxicity, 
low-dose intermittent i.v. CYC was next investigated. Th  e 
Euro-Lupus Nephritis Trial compared a NIH-like high-
dose regimen of i.v. CYC (six monthly pulses followed by 
two quarterly pulses) with the Euro-Lupus low-dose 
regimen (six pulses of i.v. CYC every 2 weeks at a ﬁ  xed 
dose of 500 mg) [121]. Th   e rates of renal remission were 
not statistically diﬀ  erent between the two groups, but 
treatment-related adverse eﬀ  ects were less frequent with 
the reduced-dose regimen. Limitations of the Euro-
Lupus trial include a population with relatively milder 
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proteinuria 2.5 to 3.5 g/day for both groups), with almost 
85% of the patients being Caucasian. Nevertheless, low-
dose i.v. CYC is an option – particularly for low-risk 
Caucasians with less severe PLN.
Noncyclophosphamide induction regimens: 
mycophenolate mofetil
Recently, mycophenolate mofetil (MMF) has emerged as a 
promising alternative therapy for both induction and 
maintenance treatment of LN. Mycophenolic acid, the 
active metabolite of MMF, is an inhibitor of the rate-
limiting enzyme (inosine monophosphate dehydro  ge  nase) 
involved in de novo purine synthesis [122]. As lymphocytes 
do not possess a salvage pathway for the generation of 
these nucleotides, MMF results in selective blockade of B-
cell and T-cell proliferation. Unlike CYC, mycophenolic 
acid has little impact on other tissues with high 
proliferative activity (for example, neutrophils, skin, 
intestine, bone marrow, gonads), which do possess a 
salvage pathway for nucleotide synthesis. Th   is accounts for 
the metabolite’s more favorable toxicity proﬁ  le com  pared 
with CYC, and this renders MMF particularly attractive.
As listed in Table 2, Chan and colleagues randomized 
42 patients with PLN to 6 months of induction with 
MMF (2 g/day) or oral CYC (2.5 mg/kg/day), both with 
concurrent oral prednisolone [123]. During the mainte-
nance phase, those patients in the MMF arm continued 
the drug at a reduced dose (1 g/day) and those in the 
CYC arm switched to azathioprine (AZA) (1.5 mg/kg/
Table 2. Randomized controlled studies in lupus nephritis
Drug and      Number and  Follow-up 
reference  Description  Primary endpoint  type of patients  duration  Results
CYC [118] Patients randomized to i.v. 
CYC vs. p.o. CYC, p.o. CYC + 
AZA, AZA, or prednisone 
Time to kidney failure n = 107, mainly class III 
and IV LN
7 years Time to ESRD is signifi  cantly 
longer in patients receiving 
i.v. CYC compared with those 
receiving steroids alone
CYC [121] Patients randomized to high-
dose (500 to 
1,000 mg/m2) monthly i.v. 
CYC for 6 months vs. low-
dose i.v. CYC regimen 500 mg 
every 2 weeks x six doses
Treatment failure 
(doubling of sCr, 
absence of primary 
response or occurrence 
of a fl  are)
n = 90, class IV LN, 85% 
Caucasian
41 months Induction therapy with low-
dose CYC is as eff  ective as 
high-dose CYC
MMF [123] Patients randomized to 
6 months induction with 
MMF (2 g/day) or oral 
CYC (2.5 mg/kg/day) + 
prednisolone
Incidence of complete 
remission
n = 42, class IV LN, 100% 
Chinese
12 months Induction therapy with MMF is 
as eff  ective as oral CYC
MMF [124] Patients randomized to 
monthly i.v. CYC or MMF 
(3 g/day)
Incidence of complete 
remission at 6 months 
n = 140, class IV, 56% 
African American
6 months MMF was not inferior to i.v. CYC 
for induction of remission. In 
fact, MMF was more eff  ective 
and better tolerated than i.v. 
CYC at inducing remission
MMF [125] Patients randomized to 
MMF or monthly i.v. CYC for 
induction
Prespecifi  ed decrease in 
urine protein/creatinine 
ratio and improvement 
in sCr
n = 370, classes III to V 
LN, 75% Caucasian
6 months MMF is not superior to i.v. 
CYC as induction therapy. 
No signifi  cant diff  erences in 
response rate between the two 
groups. Adverse events were 
similar
MMF [126] Patients randomized to 
quarterly i.v. CYC, MMF, or 
AZA for maintenance after 
induction with i.v. CYC
Incidence of patient and 
kidney survival
n = 59, classes III and IV 
LN, African American 
and Hispanic
72 months MMF and AZA are both 
effi   cacious and safer than i.v. 
CYC for maintenance therapy
AZA [126] Patients randomized to 
quarterly i.v. CYC, MMF, or 
AZA for maintenance after 
induction with i.v. CYC
Incidence of patient and 
kidney survival
n = 59, classes III and IV 
LN, African American 
and Hispanic
72 months MMF and AZA are both 
effi   cacious and safer than i.v. 
CYC for maintenance therapy
AZA, MMF (Houssiau 
and colleagues, 
2010)
Patients randomized to MMF, 
or AZA for maintenance after 
induction with low-dose 
i.v. CYC
Time to renal fl  ares n = 103, classes III and IV 
LN, European
Minimum 3 years No signifi  cant diff  erence in renal 
fl  ares with MMF and AZA as 
maintenance therapy
Rituximab (Rovin 
and colleagues, 
2009)
Patients randomized to 
MMF or MMF + rituximab for 
induction therapy
Incidence of complete 
or partial renal remission
n = 144, classes III and 
IV LN
52 weeks Rituximab does not have an 
additive benefi  t to MMF for 
induction therapy
AZA, azathioprine; CYC, cyclophosphamide; ESRD, end-stage renal disease; i.v., intravenous; LN, lupus nephritis; MMF, mycophenolate mofetil; p.o., oral; sCr, serum 
creatinine.
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Page 6 of 12day) for 6 months. Th  is study suggested that induction 
treatment with MMF was as eﬀ  ective as oral CYC, but 
with fewer side eﬀ  ects. Although this study included only 
Chinese patients and excluded patients with poor prog-
nostic indicators, a more recent study has demonstrated 
the increased eﬃ   cacy of MMF induction in a high-risk, 
multiracial, American population in which 56% of the 
patients were African American [124] (Table 2). Limita-
tions of the latter study included its short follow-up 
duration, the crossover design and the fact that patients 
with rapidly progressive renal failure were excluded.
Later on, another US study, the Aspreva Lupus 
Management Study, comprising high risk population 
with proliferative LN demonstrated similar eﬃ   cacies of 
MMF and intravenous CYC as induction therapies [125] 
(Table 2). Furthermore, it was observed that, race, 
ethnicity and geographical region may aﬀ  ect treatment 
response; more Black and Hispanic patients responded to 
MMF than i.v. CYC. As the study was not designed for 
this sub-group analysis, it is diﬃ     cult to draw ﬁ  rm 
conclusions about their importance.
Maintenance therapies
Once a patient has attained remission, immunosup  pres-
sion is given to help maintain remission, to prevent 
relapse, and to decrease the risk of developing ESRD. In 
the NIH trials, i.v. CYC at 3-month intervals for 18 to 
24 months was used as maintenance therapy [118]. In the 
past decade, sequential regimens of short-term CYC 
induction therapy, followed either by MMF or AZA 
maintenance, have proven to be eﬃ   cacious and safe, with 
reduced hazards, compared with long-term exposure to 
CYC. Using a similar regime, Contreras and colleagues 
have reported similar ﬁ  ndings in a randomized controlled 
study that included a large number of high-risk non-
Caucasian patients, predominantly African Americans 
and Hispanics [126] (Table 2). In a recently concluded 
Euro-Lupus Nephritis Trial multi-center trial (MAINTAIN 
Nephritis Trial) comprising 105 patient with proliferative 
LN, no signiﬁ  cant diﬀ  erence in renal ﬂ  ares was observed 
between AZA and MMF as maintenance therapy over 
3 years of follow up [127].
Another trial comparing MMF against AZA as 
remission-maintaining treatment for PLN following 
induction with a short course of intravenous CYC, the 
main  tenance phase of the Aspreva Lupus Management 
Study [125], has recently been concluded and the results 
were presented at the American Society of Nephrology 
Meeting in 2010.  It did not show any diﬀ  erence in renal 
ﬂ  ares between the two maintenance therapies (Table 3).
Adjunctive therapy
As co-morbidities can signiﬁ  cantly worsen outcome, these 
have to be actively managed in LN. Accelerated 
athero  genesis and coronary vascular disease are now 
recognized complications of SLE [128]. Recognized risk 
factors include hypertension, hyperlipidemia, nephrotic 
syn  drome, prolonged corticosteroid use, anti  phos-
pholipid antibody syndrome and, in some cases, the 
vascular risks asso  ciated with chronic kidney disease. 
Th   is underscores the importance of aggressively 
managing these modiﬁ    able risk factors [129]. Although 
few data are available speciﬁ    cally for patients with LN, it 
appears prudent to apply the knowledge gleaned from 
studying the general population with chronic kidney 
disease. Tight blood pressure control, the use of 
angiotensin-converting en  zyme inhibi  tors and/or angio-
tensin receptor blockers, and correction of dyslipid  emia 
are thus strongly recom  mended. More  over, patients with 
chronic kidney disease should be screened and treated 
for complications such as anemia and bone and mineral 
disease (secondary hyper  para  thyroidism, hyperphospha-
temia, vitamin D deﬁ   ci  ency). In addition, measures 
should be taken to prevent glucocorticoid-induced osteo-
porosis, including the use of calcium, vitamin D supple-
ments, and bisphosphonates when necessary [130].
Novel approaches in the treatment for PLN
Despite recent strides in the treatment of LN, about 20% 
of patients do not respond but progress to ESRD. 
Moreover, toxicity of the current immunosuppressive 
regimens remains unacceptably high. With a better 
under  standing of the molecular mechanisms underlying 
LN, as discussed above (Figure 1), several newer and 
targeted therapeutic approaches are currently being 
tested, aimed at improved eﬃ   cacy and reduced toxicity. 
Th  ese include LPJ394, rituximab, epratuzumab, belimu-
mab, and abatacept, as summarized in Table 3. Th  is 
targeted therapy constitutes another area of research that 
is rapidly burgeoning with ongoing contributions from 
academia and from industry. As ongoing eﬀ  orts in trans-
criptomics and proteomics further elucidate the 
molecular basis of lupus pathogenesis, the drugs that 
dominate the therapeutic landscape are likely to evolve 
rapidly.
Treatment of resistant lupus nephritis
While there has been signiﬁ  cant improvement in how we 
manage LN, up to 20% of patients with LN are refractory 
to initial induction treatment, while 30 to 50% of patients 
still progress to ESRD [136]. Many of these patients have 
poor prognostic factors including African American race, 
delayed initiation of treatment, poor compliance, and 
arterial hypertension at presentation [137]. More aggres-
sive CYC regimens have been tried in these patients. One 
method involves the use of oral CYC instead of i.v. CYC. 
As the cumulative dose is higher in patients who receive 
daily oral dosing, it may be expected to be more eﬀ  ective 
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should be limited to 6 months and should only be given 
to patients with multiple poor prognostic factors [138].
Intravenous immunoglobulin
Intravenous immunoglobulin is another modality that 
has been tested.  Th  e eﬃ     cacy of intravenous immuno-
globulin in controlling disease activity and ameliorating 
classical disease manifestations ranges from 33 to 100% 
in diﬀ  erent case series surveyed in a recent meta-analysis 
[139]. Other analyses have documented similar positive 
results, with particular improvements in the clinical and 
histological readouts of nephritis [140]. Despite en-
courag  ing reports describing the eﬃ   cacy of intravenous 
immunoglobulin therapy in SLE, most of the data are 
based on case reports and small series. Furthermore, the 
long-term eﬃ   cacy, optimal dosage and duration of therapy 
of intravenous immunoglobulin in LN remain to be 
established. Nevertheless, intravenous immuno  globulin 
can be considered in patients with LN either as salvage 
immunotherapy in severe cases that are nonresponsive or 
nontolerant to conventional treatment or in patients who 
experience severe infectious complications.
Calcineurin inhibitors
Open-labeled uncontrolled studies have reported eﬃ   cacy 
and tolerability of cyclosporin A in the treatment of PLN 
[141]. No published comparative trials between CYC and 
cyclosporin A in adult SLE patients are currently avail-
able. In an open study of 11 patients with LN, eight of 
whom were resistant or intolerant to CYC or AZA, 
signiﬁ  cant improvement in proteinuria and anti-dsDNA 
titers was reported after treatment with cyclosporin A for 
12 months [142].
Immunoablative therapy
Immunoablative therapy (that is, daily high doses of CYC 
followed by granulocyte colony-stimulating factor) 
Table 3. Novel therapeutic regimes in lupus nephritis targeting specifi  c pathogenic molecules
Drug and  Description of     
reference  drug or target  Mechanism of action  Details of trial  Outcome of trial
LPJ394 (riquent, 
abetimus sodium) 
[131,132]
Four dsDNA 
helices coupled to 
polyethylene scaff  old
Neutralizes anti-DNA 
antibodies in serum and 
tolerizes anti-DNA B cells 
n = 230, classes III to V lupus nephritis; 
randomized, placebo-controlled, for 
76 weeks
Anti-DNA and complement profi  les 
improved with LJP394, but no 
signifi  cant diff  erence in time to renal 
fl  ares between the two groups
Rituximab [133] Chimeric antibody to 
CD20 on B cells
Agent targets and 
silences or removes B cells 
(some of which produce 
autoantibodies)
n = 10 lupus nephritis patients, 
375 mg/m2, 4 weekly infusions, + oral 
CS; duration 12 months
5/10 achieved complete remission 
sustained for 1 year; 3/10 had partial 
remission
Epratuzumab [134] Humanized antibody 
to CD22 on B cells
Agent targets and 
silences or removes B cells 
(some of which produce 
autoantibodies)
n = 14 (4 with nephritis); open-label 
study. Four doses of 360 mg/m2 given 
every 2 weeks; duration 32 weeks
Total BILAG scores decreased by 
≥50% in all 14 patients at some point 
during the study. It was well tolerated
Belimumab 
(lymphostat B) [135]
Humanized antibody 
to Blys (or BAFF)
Agent blocks activation of 
B cells by countering Blys 
activation of B cells
n = 449 (22 to 35% with nephritis); 
phase II randomized double-blind 
placebo-controlled study. Patients 
receive placebo or 1, 4 or 10 mg/kg 
belimumab at days 0, 14, 28 and then 
every 28 days + standard-of-care 
treatment; duration 52 weeks
No signifi  cant diff  erences in primary 
end-points (reduction in SELENA-
SLEDAI scores or time to renal fl  ares). 
However, patients on belimumab 
had signifi  cantly better physicians’ 
subjective assessment scores and 
Short Form 36 scores)
Orencia (abatacept) 
(www.clinical 
trials.gov ID: 
NCT00774852)
Fusion protein of 
CTLA4 linked to Fc 
portion of human IgG1
Agent blocks T-cell:B-cell 
cross-talk by blocking CD28–
CD80/CD86 interactions
n = 100; randomized, double-blind, 
controlled, phase II multicenter 
trial of CTLA4Ig (abatacept) 
plus cyclophosphamide vs. 
cyclophosphamide alone in the 
treatment of lupus nephritis
Currently recruiting
Rontalizumab 
(www.clinical 
trials.gov ID: 
NCT00962832)
Humanized antibody 
to type 1 interferon
Agent blocks the function 
of the cytokine, interferon 
type 1
n = 210; phase II, randomized, 
double-blind, placebo-controlled 
study to evaluate the effi   cacy and 
safety of rontalizumab in patients with 
moderately to severely active systemic 
lupus erythematosus
Active: not recruiting patients at 
present
MEDI-545 (www.
clinical trials.gov ID: 
NCT00657189)
Fully human antibody 
to IFN-α
Agent blocks the function 
of the cytokine, interferon 
type 1
n = 80; phase 2A, randomized, double-
blind, placebo-controlled, parallel-
dose study to evaluate the safety and 
tolerability of multiple subcutaneous 
doses of MEDI-545, in subjects with SLE
Active: not recruiting patients at 
present
BILAG, British Isles Lupus Assessment Group; CS, corticosteroids; SELENA, Safety of Estrogens in Lupus Erythematosus: National Assessment; SLE, systemic lupus 
erythematosus; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index.
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plan  tation is another option that can be entertained in 
severe refractory LN. Clinical remissions have been 
observed in about 65% of cases [143]. However, the 
relatively high incidence of toxicities and mortality 
remains a concern.
Conclusion
LN remains a major manifestation of SLE, as 60% of SLE 
patients may develop this end-organ involvement. Th  e 
epidemiology and clinical manifestations of LN have 
been well studied over the past few decades. Th  e 2003 
addition to the ISN/RPS classiﬁ  cation of the modiﬁ  ed 
WHO schema of histo  logical classiﬁ   cation of LN has 
signiﬁ   cantly improved how the disease is classiﬁ  ed, 
managed and prognos  ticated. In terms of the underlying 
pathogenic mecha  nisms, we have gained signiﬁ  cant 
insights regarding the cells and molecules that orches-
trate the systemic as well as the target organ phases of the 
disease. How we manage LN has also evolved signiﬁ  cantly 
over the past decade, thanks to multiple clinical trials. 
Currently, the optimal induction therapy appears to be 
i.v. CYC or oral myco  phenolate, while maintenance is 
best achieved using oral mycophenolate, AZA or i.v. 
CYC. Newer targeted therapeutics built upon recent 
molecular insights are likely to revolutionize how LN is 
managed in the clinic in the coming years.
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